Comparison of the incidences of HBsAg loss and hepatocellular carcinoma development between HBeAg-negative patients who discontinued or continued entecavir therapy

Chen Chien-Hung; Peng Cheng-Yuan; Hu Tsung-Hui; Lu Sheng-Nan; Wang Jing-Houng; Hung Chao-Hung

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Comparison of the incidences of HBsAg loss and hepatocellular carcinoma development between HBeAg-negative patients who discontinued or continued entecavir therapy

【24h】

Comparison of the incidences of HBsAg loss and hepatocellular carcinoma development between HBeAg-negative patients who discontinued or continued entecavir therapy

机译：HBSAG损失和肝癌患者患者肝癌损失和肝癌患者患者的发病率的比较

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2017年第1期|共1页
作者
Chen Chien-Hung; Peng Cheng-Yuan; Hu Tsung-Hui; Lu Sheng-Nan; Wang Jing-Houng; Hung Chao-Hung;
展开▼
作者单位

Chang Gung Mem Hosp Kaohsiung Med Ctr Kaohsiung Taiwan;

China Med Univ Hosp Taichung Taiwan;

Chang Gung Mem Hosp Kaohsiung Med Ctr Kaohsiung Taiwan;

Chang Gung Mem Hosp Kaohsiung Med Ctr Kaohsiung Taiwan;

Chang Gung Mem Hosp Kaohsiung Med Ctr Kaohsiung Taiwan;

Chang Gung Mem Hosp Kaohsiung Med Ctr Kaohsiung Taiwan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Comparison of the incidences of HBsAg loss and hepatocellular carcinoma development between HBeAg-negative patients who discontinued or continued entecavir therapy [J] . Chen Chien-Hung, Peng Cheng-Yuan, Hu Tsung-Hui, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：HBSAG损失和肝癌患者患者肝癌损失和肝癌患者患者的发病率的比较
2. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B (vol 23, pg 677, 2018) [J] . Papatheodoridis George V., Rigopoulou Eirini I., Papatheodoridi Margarita, Antiviral therapy . 2018,第8期

机译：Daring-B：在非肝硬化HBEAG阴性慢性乙型肝炎中的HBsAg丧失之前，停止有效的Entecavir或Tenofovir Disoproxil Mumarate长期治疗（Vol 23，PG 677,2018）
3. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B [J] . Papatheodoridis George V, Rigopoulou Eirini I, Papatheodoridi Margarita, Antiviral therapy . 2018,第8期

机译：大胆-B：在非肝硬化HBEAG阴性慢性乙型肝炎中丧失HBsAg损失前，停止有效的Encavir或Tenofovir Disoproxil Mumarate长期治疗
4. Hepatic Iron Accumulation and incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C [C] . Namiki Izumi, Yasuhiro Asahina, Osamu Noguchi, Yamaguchi Symposium on Liver Disease . 2003

机译：慢性丙型肝炎患者肝脏铁累积和肝细胞癌发病率
5. Trends in hepatocellular carcinoma incidence and mortality in Canada from 1976 through 2000 [D] . Pocobelli, Gaia 2004

机译：1976年至2000年加拿大肝细胞癌发病率和死亡率的趋势
6. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL [O] . Chih-Chien Yao, Chao-Hung Hung, Tsung-Hui Hu, -1

机译：HBsAg≤200 IU / mL的HBeAg阴性患者中核苷类似物停药后HBV复发的发生率和预测因素
7. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study [O] . I-Cheng Lee, Sien-Sing Yang, Chieh-Ju Lee, 2018

机译：HBSAG损失后HBSG-阴性慢性乙型肝炎术后HBsAg损失的发病率和预测因子：多中心，长期随访研究

Comparison of the incidences of HBsAg loss and hepatocellular carcinoma development between HBeAg-negative patients who discontinued or continued entecavir therapy

著录项

相似文献

相关主题

期刊订阅